What is the highest dose of semaglutide you can take?

Why does semaglutide have a maximum dose at all?

GLP-1 medicines work by slowing gastric emptying and signalling fullness to the brain. At higher doses the appetite-suppressing effect is stronger, but so is the potential for gastrointestinal side effects, nausea, vomiting, indigestion and similar. The dose ladder exists to give your system time to adjust at each level before moving up. Prescribers are not racing to reach the top rung; the goal is the lowest dose that delivers a meaningful clinical response, held long enough to be useful.

For Wegovy specifically, the licensed schedule runs 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, each held for roughly four weeks. The 7.2 mg dose sits above 2.4 mg as a further option for adults with obesity (BMI ≥ 30) who tolerate treatment and need additional effect. A prescriber decides whether moving to 7.2 mg is appropriate, it is not automatic. The full Wegovy overview covers the licence and clinical background in more detail.

Worth noting: semaglutide is also used under the brand name Ozempic for type 2 diabetes, at different doses. If you are wondering what the highest dosage of semaglutide you can take actually is, it is important to understand that the 7.2 mg figure applies specifically to Wegovy in the weight-management licence, not to Ozempic, and the two are not interchangeable. Ozempic is not prescribed for weight loss. The NHS medicines page on semaglutide covers both indications if you want the regulatory detail from a primary source.

What did trials at the highest dose actually show?

The question most people are really asking is whether 7.2 mg is worth it. The honest answer from the trial data: it moves the results meaningfully. At 2.4 mg weekly, the STEP 1 trial (68 weeks, adults with obesity without diabetes) showed an average weight reduction of around 15%, a figure established in the original STEP 1 paper published in the New England Journal of Medicine. At 7.2 mg over 72 weeks, trials reported approximately 20.7% average weight loss.

That brings 7.2 mg semaglutide much closer to the results seen with tirzepatide (Mounjaro), which produced around 20–21% average loss at its highest dose in SURMOUNT-1. The gap between the two medicines has narrowed. Whether that difference matters clinically for a specific person depends on their circumstances, their response to earlier doses, and their tolerability, which is exactly the kind of assessment a prescriber works through. If you are considering how the two medicines compare on results, our page on the highest Wegovy dose walks through the evidence side by side.

One thing to flag honestly: if you are midway through a Wegovy course and hoping the 7.2 mg dose will simply be offered at your next review, that is not how it works. Moving up requires a fresh clinical assessment and evidence that the current dose is well-tolerated. That process protects you.

Who can reach the 7.2 mg dose, and what are the side-effect considerations?

The MHRA's 7.2 mg approval is for adults with a BMI of 30 or above. It does not apply to the separate cardiovascular-risk indication, and it is not licensed for anyone with a BMI below 30. Ethnic-background adjustments to BMI thresholds exist under UK guidance, so the threshold a prescriber applies may differ slightly depending on background.

Side effects at higher doses follow the same pattern as the rest of the schedule, just with a higher likelihood: nausea and other gastrointestinal symptoms are the most commonly reported, typically most noticeable in the first couple of weeks at any new dose and settling thereafter. The NHS semaglutide page lists the full side-effect profile with guidance on when to seek help.

Pancreatitis is a less common but serious consideration. Severe, persistent stomach pain that spreads to the back (with or without vomiting) warrants urgent medical attention. The MHRA highlighted pancreatitis risk across GLP-1 medicines in a Drug Safety Update in January 2026; reporting suspected side effects via the Yellow Card scheme at yellowcard.mhra.gov.uk is encouraged. Pregnancy, breastfeeding, and trying to conceive are contraindications for the full semaglutide dose range. Women using oral contraceptives may wish to discuss absorption considerations with their prescriber before starting or increasing doses. These are conversations to have before a prescription is written, not after.

One thing our prescribers hear fairly often: people arrive having done a lot of research, armed with a target dose they've read about online, and feeling frustrated that they can't simply start there. That frustration is understandable. The titration schedule exists for good reason, but it can feel slow when you're motivated and ready. If questions about cost alongside dose come up during that process, our Wegovy cost comparison page puts UK private pricing in context.

How is the 7.2 mg dose delivered, injection or tablet?

At launch, 7.2 mg was administered as three 2.4 mg pens in a single weekly injection sequence. The dedicated single-dose 7.2 mg pen approved on 14 April 2026 simplifies that: one weekly injection, pre-set, with an auto-dosing mechanism, a covered needle, and a lock after use. It operates in the same way as the existing Wegovy pen design, just at the higher dose.

It is worth being clear: the highest semaglutide dose currently available is injection-based. The oral Wegovy tablet (approved by the MHRA on 11 June 2026 as the first oral GLP-1 for weight management in the UK) reaches a maintenance dose of 25 mg daily, but that is a different formulation with its own titration schedule. Comparing injection and tablet doses numerically is not meaningful because oral bioavailability of semaglutide is much lower than subcutaneous; the medicines are not dose-equivalent. If the tablet route interests you, our weight-loss treatment overview covers both formulations.

Storage for the injection pen is the same as for other Wegovy doses: refrigerated at 2–8°C, with a limited room-temperature window set out in the Patient Information Leaflet. Always follow the leaflet's instructions rather than guidance online, as the window varies by pen format.

Semaglutide at any dose is a prescription-only medicine. If you'd like a clinical assessment to find out whether Wegovy is right for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.